CorMedix Inc. (CRMD) Balance Sheet

The dramatic expansion in assets, particularly cash, suggests the company successfully accessed capital markets to support its growth phase, moving from a pre-commercial to a well-capitalized commercial entity. This shift is reflected in the equity base growing from $84.7M to $460.8M over the same period, indicating the transformation was equity-funded rather than debt-driven, which provides a solid foundation for the operational ramp.

The current ratio of 2.56 in Q2 2026, while lower than the peak of 7.82 in Q2 2025, still indicates a very healthy liquidity position. The large cash balance, which represents over 28% of total assets, suggests the company has ample runway to fund its commercial operations and potential strategic initiatives without immediate need for additional financing.

The debt-to-equity ratio of 0.31 in Q2 2026, while a substantial increase from near-zero levels, remains conservative and suggests the leverage is being used strategically rather than out of necessity. This balanced approach to capital structure appears designed to optimize the cost of capital while maintaining financial flexibility during the critical commercial ramp phase.

The concentration of assets in goodwill and intangibles, which now represent about 3.3% of total assets, suggests the company may have acquired technology or commercial rights to support its product launch. This asset mix indicates an intellectual property-driven business model, but also introduces potential impairment risk if the acquired assets fail to generate expected returns.

The significant equity expansion appears to be the result of successful capital raises that have provided the financial foundation for the commercial launch. However, the persistent negative retained earnings indicate the company has not yet generated cumulative profits, suggesting the equity strength is externally provided rather than internally generated, which warrants monitoring as the business matures.